Clinical study of liraglutide in the treatment of coronary heart disease with type 2 diabetes mellitus
Objective To analyze the clinical effect of liraglutide in the treatment of coronary heart disease with type 2 diabetes mellitus.Methods 102 patients with coronary heart disease and type 2 diabetes mellitus were divided into a control group and an observation group according to computer random grouping method.The control group was treated with metformin,and the observation group was treated with metformin and liraglutide.Both groups were compared in terms of cardiac function indicators(left ventricular ejection fraction,left ventricular end-diastolic diameter,cardiac output and QT dispersion),blood glucose indicators[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),glycosylated hemoglobin(HbA1c),homeostasis model assessment of insulin resistance(HOMA-IR),β-cell function(HOMA-β)].Results After treatment,the observation group had left ventricular ejection fraction of(56.10±9.06)% ,left ventricular end-diastolic diameter of(45.80±6.64)mm,cardiac output of(5.60±1.18)L/min,and QT dispersion of(45.03±6.31)ms,which were better than(50.50±7.90)% ,(50.20±7.07)mm,(4.88±1.01)L/min,and(53.77±8.50)ms in the control group(P<0.05).After treatment,the observation group had 2 h PG of(7.28±1.30)mmol/L,FPG of(6.06±0.27)mmol/L and HbA1c of(5.88±0.32)% ,which were better than(8.71±1.20)mmol/L,(7.01±0.76)mmol/L and(6.65±0.52)% in the control group(P<0.05).After treatment,the observation group had HOMA-β and HOMA-IR was better than the control group(P<0.05).Conclusion The combination of metformin and liraglutide can effectively improve the patients'cardiac function indicators,blood glucose indicators and insulin resistance status,suggesting that this type of treatment model has excellent application prospects and can be further applied in future work processes.
NETL
NSTL
万方数据
